Russia Approves Its Local Company BIOCAD’s Infliximab Biosimilar for Ankylosing Spondylitis

Russian regulators have approved the Russian company BIOCAD’s infliximab biosimilar as a treatment for rheumatoid arthritis and ankylosing spondylitis. The approval was based on extensive preclinical-trial studies and trial results showing that BIOCAD is similar to Janssen’s Remicade, the company said. BIOCAD experts the results to support its product’s approval…